Latest by Myles Helfand

Fighting HIV in the Trump Era: U.S. Advocates Speak Out

We asked HIV community leaders how their priorities have changed since Trump’s election – and what they see as the most important challenges to the fight against HIV under a Trump presidency.

By Myles Helfand

This Week in HIV Research: Can Vaginal Microbiome Affect HIV Drug Levels?

Among our featured reports this week, we learn about how the vaginal microbiome may affect antiretroviral concentrations in the genital tract, and we look at the potential impact of global supply-chain interruptions on HIV drug resistance.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: How to Cut U.S. HIV Incidence by 250,000 in 20 Years

Among our four featured reports this week, we learn about the critical intersection between HIV treatment access and reduced HIV incidence in the U.S. -- and about the value of replacing placebos with PrEP in clinical trials on HIV prevention.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: For Many U.S. MSM, Tenuous Connections to Care

Among the research we review this week, we highlight data showing just how far the U.S. still has to go in keeping HIV-positive people within some high-risk communities connected to care after they're diagnosed.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: 'Massive Loss of Life'

Among this week's collection of four study summaries are data indicating that reducing U.S. foreign aid for HIV-fighting efforts is a really bad idea, no matter which way you cut it.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: A New Glimpse Into HAND

We look at peroxisomes and neurocognitive impairment; injectable cabotegravir for PrEP; genital bacteria and HIV risk; and how HIV diagnosis relates to intimate partner violence among pregnant women.

By Barbara Jungwirth and Myles Helfand

HIV Community Remembers Mark Wainberg, Leader and Prominent Researcher

The HIV community has reacted with shock and sadness to news that Mark Wainberg, Ph.D., died on April 12.

By Myles Helfand and Ken Stockwell

Long-Acting HIV Treatment: 5 Myths and Realities

Long-acting antiretrovirals: Are they the future of HIV treatment or will the future pass them by? Researcher Charles W. Flexner recently addressed several common myths.

By Myles Helfand

Women's HIV Status, Viral Suppression Tied to Differences in Cognitive Performance Over Time

Women with HIV tend to perform worse than HIV-negative women on cognitive performance tests, even after many years on treatment, new research finds -- but trends differed depending on the test and on women's treatment success.

By Myles Helfand

Top HIV Researcher Hails a Resurgent Antiretroviral Pipeline

Paul Sax, M.D., discusses the clinical importance of new drugs in development highlighted at CROI 2017 -- and about what else is on the near horizon when it comes to antiretroviral therapies for HIV.

By Myles Helfand